2-(氰基甲基)-5-氟苯甲腈 | 256951-82-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(氰基甲基)-5-氟苯甲腈
• 中文别名: 苯乙酰腈,2-氰基-4-氟-；2-氰基-4-氟苯乙腈
• 英文名称: 2-(cyanomethyl)-5-fluorobenzonitrile
• CAS: 256951-82-3
• 化学式: C₉H₅FN₂
• mdl: MFCD09923750
• 分子量: 160.151
• InChiKey: XQBWYQLJKYOIER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  47.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  2-(氰基甲基)-5-氟苯甲腈 在 盐酸 、 caesium carbonate 作用下， 以 二甲基亚砜 、 乙酸乙酯 为溶剂， 反应 24.08h， 生成 4-cyano-4-(2-cyano-4-fluorophenyl)piperidine
  参考文献：
  名称：

  In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α_1A Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia

  摘要：

  alpha(1) Adrenergic receptors mediate both vascular and lower urinary tract tone, and alpha(1) receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified, with the alpha(1A) receptor being most prevalent in lower urinary tract tissue. This paper explores 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective alpha(1A) receptor subtype antagonists. In receptor binding assays, these types of compounds generally display K-i values for the alpha(1a) receptor subtype <1 nM while being greater than 100-fold selective versus the alpha(1b) and alpha(1d) receptor subtypes. Many of these compounds were also evaluated in vivo and found to be more potent than terazosin in both a rat model of prostate tone and a dog model of intra-urethral pressure without significantly affecting blood pressure. While many of the compounds tested displayed poor pharmacokinetics, compound 48 was found to have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the alpha(1a) over the alpha(1d) and alpha(1d) receptors as well as its favorable pharmacokinetic profile, 48 has the potential to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.

  DOI：

  10.1021/jm990612y
• 作为产物：
  描述：

  2,5-二氟苯腈 在 caesium carbonate 、 三氟乙酸 作用下， 以 二甲基亚砜 为溶剂， 反应 6.0h， 生成 2-(氰基甲基)-5-氟苯甲腈
  参考文献：
  名称：

  In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α_1A Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia

  摘要：

  alpha(1) Adrenergic receptors mediate both vascular and lower urinary tract tone, and alpha(1) receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified, with the alpha(1A) receptor being most prevalent in lower urinary tract tissue. This paper explores 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective alpha(1A) receptor subtype antagonists. In receptor binding assays, these types of compounds generally display K-i values for the alpha(1a) receptor subtype <1 nM while being greater than 100-fold selective versus the alpha(1b) and alpha(1d) receptor subtypes. Many of these compounds were also evaluated in vivo and found to be more potent than terazosin in both a rat model of prostate tone and a dog model of intra-urethral pressure without significantly affecting blood pressure. While many of the compounds tested displayed poor pharmacokinetics, compound 48 was found to have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the alpha(1a) over the alpha(1d) and alpha(1d) receptors as well as its favorable pharmacokinetic profile, 48 has the potential to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.

  DOI：

  10.1021/jm990612y

文献信息

• Alpha 1A adrenergic receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06339090B1

  公开（公告）日：2002-01-15

  This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

  这项发明涉及某些新颖化合物及其衍生物，它们的合成以及它们作为α1a肾上腺素受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生。这些化合物在其能够放松富含α1a受体亚型的平滑肌组织方面具有选择性，同时不会引起低血压。这样的组织之一是围绕尿道内膜的组织。因此，这些化合物的一个用途是通过减少尿液流动的阻碍，为患有良性前列腺增生的男性提供急性缓解。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合，从而实现对良性前列腺增生影响的急性和慢性缓解。
• [EN] ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY<br/>[FR] COMPOSÉS ANTIBACTÉRIENS À LARGE SPECTRE D'ACTIVITÉ
  申请人：ACRAF

  公开号：WO2016096686A1

  公开（公告）日：2016-06-23

  The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

  本发明涉及新型抗菌化合物，含有它们的药物组合物以及它们作为抗微生物药物的用途。
• [EN] FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF<br/>[FR] LIGANDS CRBN DE GLUTARIMIDE FUSIONNÉS ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2021011631A1

  公开（公告）日：2021-01-21

  The present invention provides compounds, compositions thereof, and methods of using the same. The present invention also relates to compounds and methods useful for binding and modulating the activity of cereblon (CRBN), especially for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

  本发明提供了化合物、其组合物以及使用它们的方法。本发明还涉及与结合和调节 cereblon (CRBN) 活性有关的化合物和方法，特别是用于抑制 CRBN 和治疗 CRBN 介导的疾病的方法。
• Regioselective Access to 3-Aryl-1-aminoisoquinolines via Nickel(I)-Catalyzed C–C and C–N Cascade Coupling Reactions from the Substituted 2-(Cyanomethyl)benzonitriles
  作者：Xicheng Yang、Haihua Yu、Yulong Xu、Liming Shao

  DOI：10.1021/acs.joc.8b01159

  日期：2018.9.7

  A novel and regioselective Ni(I) catalyzed C–C and C–N cascade coupling reactions has been developed. The cascade furnishes atom-economic access to 40 3-aryl-1-aminoisoquinolines. The regioselectivity of C(sp3)-cyano group over C(sp2)-cyano group was revealed and supported by mechanism studies as well as the preliminary density functional theory (DFT) calculations.

  已经开发了一种新颖的区域选择性Ni（I）催化的C–C和C–N级联反应。级联反应使原子经济地获得40个3-芳基-1-氨基异喹啉。通过机理研究以及初步密度泛函理论（DFT）计算，揭示并支持了C（sp 3）-氰基相对于C（sp 2）-氰基的区域选择性。
• Nickel‐Catalyzed Tandem Reaction of Functionalized Arylacetonitriles with Arylboronic Acids in 2‐MeTHF: Eco‐Friendly Synthesis of Aminoisoquinolines and Isoquinolones
  作者：Qianqian Zhen、Lepeng Chen、Linjun Qi、Kun Hu、Yinlin Shao、Renhao Li、Jiuxi Chen

  DOI：10.1002/asia.201901442

  日期：2020.1.2

  example of the nickel-catalyzed tandem addition/cyclization of 2-(cyanomethyl)benzonitriles with arylboronic acids in 2-MeTHF has been developed, which provides the facile synthesis of aminoisoquinolines with good functional group tolerance under mild conditions. This chemistry has also been successfully applied to the synthesis of isoquinolones by the tandem reaction of methyl 2-(cyanomethyl)benzoates

  已经开发了在2-MeTHF中镍催化的芳基硼酸串联（2-（氰基甲基）苄腈串联/加成环的第一个例子），该化合物在温和条件下可轻松合成具有良好官能团耐受性的氨基异喹啉。通过2-（氰基甲基）苯甲酸甲酯与芳基硼酸的串联反应，该化学方法也已成功地用于异喹诺酮的合成。使用生物基和绿色溶剂2-MeTHF作为反应介质使合成过程在环境方面无害。这种化学的合成效用还通过生物活性分子的合成来表明。